Listed by the USPTO as LARA, CAROLINE MONSERRAT
Tech Center 1600 • Art Units: 1633 1636 1651 1657 1658
This examiner grants 89% of resolved cases
LARA, CAROLINE MONSERRAT examines in Tech Center 1600 and Art Unit 1633. The profile contains 9 resolved cases, an 88.9% allowance rate, and a median of 1083 days to allowance. The 14.3% interview lift indicates a positive association, but the limited resolved-case record calls for caution when using the result to predict an individual application.
Frequently represented companies include ModernaTX Inc., University of Florida Research Foundation Inc., and The Regents of the University of California. Listed firms are Troutman Pepper Locke LLP, BAUMGARTNER PATENT LAW, and Casimir Jones, S.C. Practitioners can use the profile for initial planning, while relying on the specific record for claim and interview decisions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706176 | AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH’S ATAXIA | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18555508 | PACKAGING CELLS WITH TARGETED GENE KNOCKOUTS THAT IMPROVE RETROVIRAL VECTOR TITERS | Non-Final OA | The Regents of the University of California |
| 18841883 | ENGINEERED IMMUNOMODULATORY ACCESSORY CELLS IMPROVE ALLOGENEIC ISLET TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION | Non-Final OA | CORNELL UNIVERSITY |
| 18440260 | EFFICIENT DIFFERENTIATION OF SECOND HEART FIELD CARDIAC PROGENITOR CELLS AND RIGHT VENTRICLE CARDIOMYOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18854684 | OXYGEN CARRIERS FOR MAINTAINING ORGAN VIABILITY DURING NORMOTHERMIC PERFUSION | Non-Final OA | Ohio State Innovation Foundation |
| 18763564 | HIGH-EFFICIENCY EXPRESSION VECTOR OF CIRCULAR RIBONUCLEIC ACID (circRNA) AND USE THEREOF | Non-Final OA | Zhejiang University |
| 18583301 | NUCLEIC ACID NANOPARTICLES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Final Rejection | IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC. |
| 18528348 | GENERATING QUIESCENT HEPATIC STELLATE CELLS AND THEIR USE IN LIVER MODELS | Non-Final OA | The Cleveland Clinic Foundation |
| 18842083 | PROCESS TO ENHANCE VIRAL VECTOR PRODUCTION IN CELL-CULTURE USING GLYCYL-GLUTAMINE | Non-Final OA | Evonik Operations GmbH |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy88.9% of resolved applications examined by Caroline Monserrat Lara were allowed (9 resolved cases), compared with 34.9% across Art Unit 1633 over the last five years.
This examiner's interview lift is +14.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Caroline Monserrat Lara took 1,083 days on average from filing to allowance.
Caroline Monserrat Lara examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).